Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 21, 2018

View Archived Issues

Adipose-derived regenerative cell therapy safe in patients with erectile dysfunction

Polymorphisms in miRNA-146a and IRAK1 are associated with susceptibility to SLE and MS

Harbour BioMed licenses ex-China rights to Kelun-Biotech's A-167

Common pathway may underlie schizophrenia and PD

Getting at stored mRNAs part of fragile X problem

HDAC inhibitors optimized for CNS drug-like properties and hematological safety

Phase Ib data guide Novan's development of SB-414 for atopic dermatitis

New oral selective apelin agonist AM-2995 developed for heart disease treatment

Chugai's describes candidate for the treatment of hyperphosphatemia EOS-798

Novo Nordisk reports topline PIONEER 5 results for oral semaglutide

Phase III study of MC2-01 cream in psoriasis vulgaris meets primary and secondary endpoints

Biogen identifies new NRF2 activators

Adare Pharmaceuticals describes cysteamine prodrugs

Antiangiogenic compounds synthesized at Celgene

Vectura completes pediatric studies with VR-647 for asthma

Hanmi Science patents oncolytic compounds

New Rho kinase inhibitors described by Chiesi Farmaceutici

Japanese approval for Tagrisso as first-line treatment of EGFR-mutated NSCLC

Phase II trial of TLC-599 for osteoarthritis pain meets primary and key secondary endpoints

FDA approves expanded label for Keytruda for first-line treatment of metastatic non-squamous NSCLC

Ascentage Pharma opens phase I trial of APG-2575 in hematologic malignancies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...